Gene basic information

symbol CDKN2B-AS1
name CDKN2B antisense RNA 1
location 9p21.3
alias_symbol ANRIL|RP11-145E5.4|NCRNA00089|p15AS|CDKN2B-AS|PCAT12
alias_name antisense RNA in the INK4 locus|non-protein coding RNA 89|p15 antisense RNA|CDKN2B antisense RNA (non-protein coding)|prostate cancer associated transcript 12
Cancerbladder cancer,breast cancer,cervical cancer,colorectal cancer,epithelial ovarian cancer,esophageal squamous cell cancer,gallbladder cancer,gastric cancer,hepatic cancer,lung cancer,melanoma,nasopharyngeal cancer,non-small-cell lung cancer,ovarian cancer,prostate cancer,thyroid cancer,


ANRIL is an oncogene in multiple cancers. It is significantly up-regulated in nasopharyngeal carcinoma (NPC) (1), thyroid cancer (2), non-small cell lung cancer (NSCLC) (3), esophageal squamous cell carcinoma (4), gastric cancer (5), hepatocellular carcinoma (6), gallbladder cancer (7), colorectal cancer (8), breast cancer (9), serous ovarian cancer (SOC) (10), bladder cancer (11), and prostate cancer (12). Overexpression of ANRIL is associated with clinicopathological parameters such as tumor size, TNM stage etc. and can be identified as a prognostic predictor (5, 13, 3, 10, 2). Functionally, ANRIL can promote the proliferation (11, 8, 5, 6, 3, 2), migration and invasion (6, 3, 10, 2) of cancer cells, but inhibit the apoptosis (11, 6, 3).
ANRIL plays its functions by regulating the relevant factors in these biological processes. ANRIL regulates cell proliferation and apoptosis by regulating the related function elements, like KLF2 (6, 3), INK4a, INK4b, PARP, Bax, cyt c, Smac (14, 2, 4, 3, 5, 11), caspse-9, caspase-3 and Bcl-2 (11). ANRIL can also induce angiogenesis by positively regulating VEGF-C and VEGFR-3 (15). In addition, ANRIL is involved with multidrug resistance in gastric cancer cells, and has a positive correlation with the expression of MDR1 and MRP1 (16). Its genetic polymorphisms are significantly associated with lung cancer susceptibility or platinum-based chemotherapy response (17). Besides, ANRIL can induce the stem-cell-like cells (side population cells, SP cells) and reprogram the glucose metabolism in nasopharyngeal carcinoma (NPC) cells (1). Moreover, ANRIL can participate directly in epigenetic transcriptional repression (12).

Cancer related information

download as excel csv txt

LncRNA tissue cancer type expression level oncogene/suppress gene pathway binding gene/factor associated gene/factor proliferation apoptosis migration EMT invasion metastasis prognosis tag PMID
0 ANRIL prostate prostate cancer up onco CBX7+ epigenetic modification 20541999
1 ANRIL esophagus esophageal squamous cell cancer up onco TGF-β/Smad p15INK4b- 24747824
2 ANRIL stomach gastric cancer up onco mTOR and CDK6/E2F1 pathway PRC2, +E2F1 P15-,P16-,miR-99a-,miR-449a- + - 24810364
3 ANRIL lung non-small-cell lung cancer up onco ATM-E2F1 signaling EZH2 KLF2-,p21- + - + - 25504755
4 ANRIL ovary ovarian cancer up onco MMP3+,MTA1+,FN1+,MET+,CDH1-,IMP2- + + - 25845387
5 ANRIL lung non-small-cell lung cancer up onco + + + - 25889788
6 ANRIL lung lung cancer up onco - 25964559
7 ANRIL liver hepatic cancer up onco PRC2, +SP1 KLF2- + - + + 25966845
8 ANRIL liver hepatic cancer up onco - 26045820
9 ANRIL cervix cervical cancer up onco p15- + 26408699
10 ANRIL lung non-small-cell lung cancer up onco p15- + 26408699
11 ANRIL breast breast cancer up / 26409453
12 ANRIL bladder bladder cancer up onco caspse-9+,caspase-3+,Bcl-2+,PARP-,Bax-,cyt c-,Smac- + - 26449463
13 ANRIL colorectum colorectal cancer / / 26708220
14 ANRIL lung lung cancer / / SNP,chemotherapy resistance 26729200
15 ANRIL gallbladder gallbladder cancer up onco p53-,cyclin D1+,ki-67+,caspase-3- + - 26812694
16 ANRIL stomach gastric cancer / onco -TET2 + 27027260
17 ANRIL ovary epithelial ovarian cancer up onco p15-,Bcl-2- + - - 27095571
18 ANRIL stomach gastric cancer up onco MDR1+,MRP1+ chemotherapy resistance 27121324
19 ANRIL colorectum colorectal cancer up onco VEGF-C+,VEGFR-3+,LYVE-1 + + - 27286457
20 ANRIL lung non-small-cell lung cancer up onco +c-myc + 27307748
21 ANRIL colorectum colorectal cancer up onco + + - 27314206
22 ANRIL others melanoma / / INK4a-,INK4b- 27461581
23 ANRIL thyroid thyroid cancer up onco TGF-β/Smad p15INK4b- + + + 27507052
24 ANRIL nasopharynx nasopharyngeal cancer up onco mTOR signal + cancer stem cells 27557514

Expression profile

adipose adrenal brain breast colon heart kidney leukocyte liver lung lymph node ovary prostate skeletal muscle testis thyroid tissue 0.0 0.1 0.2 0.3 0.4 0.5 fpkm 0.1 0.5 0.2 0.2 0.3 0.1 0.0 0.0 0.1 0.2 0.2 0.3 0.2 0.0 0.2 0.2 ANRIL

Expression profile in human body map


Expression profile in TCGA

Genomic feature visualization


External link


[1]. Zou ZW, Ma C, Medoro L, Chen L, Wang B, et al. (2016). LncRNA ANRIL is up-regulated in nasopharyngeal carcinoma and promotes the cancer progression via increasing proliferation, reprograming cell glucose metabolism and inducing side-population stem-like cancer cells. Oncotarget 7(38): 61741-61754. link pubmed
[2]. Zhao JJ, Hao S, Wang LL, Hu CY, Zhang S, et al. (2016). Long non-coding RNA ANRIL promotes the invasion and metastasis of thyroid cancer cells through TGF-β/Smad signaling pathway. Oncotarget 7(36): 57903-57918. link pubmed
[3]. Nie FQ, Sun M, Yang JS, Xie M, Xu TP, et al. (2015). Long noncoding RNA ANRIL promotes non-small cell lung cancer cell proliferation and inhibits apoptosis by silencing KLF2 and P21 expression. Mol Cancer Ther 14(1): 268-77. link pubmed
[4]. Chen D, Zhang Z, Mao C, Zhou Y, Yu L, et al. (None). ANRIL inhibits p15(INK4b) through the TGFβ1 signaling pathway in human esophageal squamous cell carcinoma. Cell Immunol 289(1-2): 91-6. link pubmed
[5]. Zhang EB, Kong R, Yin DD, You LH, Sun M, et al. (2014). Long noncoding RNA ANRIL indicates a poor prognosis of gastric cancer and promotes tumor growth by epigenetically silencing of miR-99a/miR-449a. Oncotarget 5(8): 2276-92. link pubmed
[6]. Huang MD, Chen WM, Qi FZ, Xia R, Sun M, et al. (2015). Long non-coding RNA ANRIL is upregulated in hepatocellular carcinoma and regulates cell apoptosis by epigenetic silencing of KLF2. J Hematol Oncol 8: 50. link pubmed
[7]. Liu B, Shen ED, Liao MM, Hu YB, Wu K, et al. (2016). Expression and mechanisms of long non-coding RNA genes MEG3 and ANRIL in gallbladder cancer. Tumour Biol 37(7): 9875-86. link pubmed
[8]. Naemura M, Tsunoda T, Inoue Y, Okamoto H, Shirasawa S, et al. (2016). ANRIL regulates the proliferation of human colorectal cancer cells in both two- and three-dimensional culture. Mol Cell Biochem 412(1-2): 141-6. link pubmed
[9]. Iranpour M, Soudyab M, Geranpayeh L, Mirfakhraie R, Azargashb E, et al. (2016). Expression analysis of four long noncoding RNAs in breast cancer. Tumour Biol 37(3): 2933-40. link pubmed
[10]. Qiu JJ, Lin YY, Ding JX, Feng WW, Jin HY, et al. (2015). Long non-coding RNA ANRIL predicts poor prognosis and promotes invasion/metastasis in serous ovarian cancer. Int J Oncol 46(6): 2497-505. link pubmed
[11]. Zhu H, Li X, Song Y, Zhang P, Xiao Y, et al. (2015). Long non-coding RNA ANRIL is up-regulated in bladder cancer and regulates bladder cancer cell proliferation and apoptosis through the intrinsic pathway. Biochem Biophys Res Commun 467(2): 223-8. link pubmed
[12]. Yap KL, Li S, Muñoz-Cabello AM, Raguz S, Zeng L, et al. (2010). Molecular interplay of the noncoding RNA ANRIL and methylated histone H3 lysine 27 by polycomb CBX7 in transcriptional silencing of INK4a. Mol Cell 38(5): 662-74. link pubmed
[13]. Hua L, Wang CY, Yao KH, Chen JT, Zhang JJ, et al. (2015). High expression of long non-coding RNA ANRIL is associated with poor prognosis in hepatocellular carcinoma. Int J Clin Exp Pathol 8(3): 3076-82. link pubmed
[14]. Xu S, Wang H, Pan H, Shi Y, Li T, et al. (2016). ANRIL lncRNA triggers efficient therapeutic efficacy by reprogramming the aberrant INK4-hub in melanoma. Cancer Lett 381(1): 41-8. link pubmed
[15]. Sun Z, Ou C, Ren W, Xie X, Li X, et al. (2016). Downregulation of long non-coding RNA ANRIL suppresses lymphangiogenesis and lymphatic metastasis in colorectal cancer. Oncotarget 7(30): 47536-47555. link pubmed
[16]. Lan WG, Xu DH, Xu C, Ding CL, Ning FL, et al. (2016). Silencing of long non-coding RNA ANRIL inhibits the development of multidrug resistance in gastric cancer cells. Oncol Rep 36(1): 263-70. link pubmed
[17]. Gong WJ, Yin JY, Li XP, Fang C, Xiao D, et al. (2016). Association of well-characterized lung cancer lncRNA polymorphisms with lung cancer susceptibility and platinum-based chemotherapy response. Tumour Biol 37(6): 8349-58. link pubmed

© Bioinformatics Group of XTBG